| Added by | JPPOUGET |
|---|---|
| Group name | EquipeJPP |
| Item Type | Journal Article |
| Title | 225Ac-Labeled Somatostatin Analogs in the Management of Neuroendocrine Tumors: From Radiochemistry to Clinic |
| Creator | Rubira et al. |
| Author | Léa Rubira |
| Author | Emmanuel Deshayes |
| Author | Lore Santoro |
| Author | Pierre Olivier Kotzki |
| Author | Cyril Fersing |
| Abstract | The widespread use of peptide receptor radionuclide therapy (PRRT) represents a major therapeutic breakthrough in nuclear medicine, particularly since the introduction of 177Lu-radiolabeled somatostatin analogs. These radiopharmaceuticals have especially improved progression-free survival and quality of life in patients with inoperable metastatic gastroenteropancreatic neuroendocrine tumors expressing somatostatin receptors. In the case of aggressive or resistant disease, the use of somatostatin derivatives radiolabeled with an alpha-emitter could provide a promising alternative. Among the currently available alpha-emitting radioelements, actinium-225 has emerged as the most suitable candidate, especially regarding its physical and radiochemical properties. Nevertheless, preclinical and clinical studies on these radiopharmaceuticals are still few and heterogeneous, despite the growing momentum for their future use on a larger scale. In this context, this report provides a comprehensive and extensive overview of the development of 225Ac-labeled somatostatin analogs; particular emphasis is placed on the challenges associated with the production of 225Ac, its physical and radiochemical properties, as well as the place of 225Ac-DOTATOC and 225Ac-DOTATATE in the management of patients with advanced metastatic neuroendocrine tumors. |
| Publication | Pharmaceutics |
| Volume | 15 |
| Issue | 4 |
| Pages | 1051 |
| Date | 2023-03-24 |
| Journal Abbr | Pharmaceutics |
| Language | eng |
| DOI | 10.3390/pharmaceutics15041051 |
| ISSN | 1999-4923 |
| Short Title | 225Ac-Labeled Somatostatin Analogs in the Management of Neuroendocrine Tumors |
| Library Catalog | PubMed |
| Extra | Number: 4 PMID: 37111537 PMCID: PMC10146019 |
| Tags | 225Ac - DOTATATE, actinium-225, first-last-coresponding, radiolabeling, radionuclide production, review, targeted alpha-therapy, targeted radionuclide therapy |
| Date Added | 2023/11/23 - 12:44:34 |
| Date Modified | 2024/12/15 - 10:30:28 |
| Notes and Attachments | Full Text (Attachment) Full Text (Attachment) Full Text (Attachment) Full Text (Attachment) Full Text (Attachment) PubMed entry (Attachment) PubMed entry (Attachment) PubMed entry (Attachment) PubMed entry (Attachment) PubMed entry (Attachment) Texte intégral (Attachment) |
Institut de Recherche en Cancérologie de
